Author: Rhonda Siddall

Novartis’ investigational oral agent alisporivir cured almost 50% more previously untreated patients with the most common form of hepatitis C when added to a standard treatment regimen, according to Phase II data presented at the European Association for the Study of the Liver congress in Berlin.

Novartis says that Onbrez is better at improving lung function and reducing breathlessness than one of the current mainstays of treatment for chronic obstructive pulmonary disease.